Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy

NCT00266318 is registered in ClinicalTrials.gov with Beth Israel Medical Center as lead sponsor.

NCT NCT00266318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00266318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy
Lead sponsor
Beth Israel Medical Center
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2005
Completion date
May 31, 2007
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c